Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $8.25 per share versus the Zacks Consensus Estimate of a loss of $6.12. This compares to earnings of $5.3 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -34.80%. A quarter ago, it was expected that this drugmaker would post earnings of $4.51 per share when it actually produced earnings of $1.68, delivering a surprise of -62.75%. Over the last four quarters, the co ...

Fox (FOXA) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non- recurring items. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have change ...

Over the last four quarters, the company has surpassed consensus EPS estimates three times. IPG Photonics (IPGP) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +200.00%. A quarter ago, it was expected that this high- powered laser maker would post earnings of $0.21 per share when it a ...

分组1 - Sportradar Group AG reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and showing a significant increase from break-even earnings per share a year ago, resulting in an earnings surprise of +325.00% [1] - The company posted revenues of $360.57 million for the quarter ended June 2025, which was 2.67% below the Zacks Consensus Estimate, but an increase from $299.69 million in the same quarter last year [2] - Sportradar Group shares have increased approximately 70.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $343.7 million, and for the current fiscal year, it is $0.33 on revenues of $1.49 billion [7] - The Zacks Industry Rank indicates that the Leisure and Recreation Products sector is currently in the bottom 27% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8]

Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +6.38%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.89 per share when it actually produced earnings of $1.02, delivering a surprise of +14.61%. Ahead of this earnings release, th ...

Company Performance - Surgery Partners reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, but down from $0.21 per share a year ago, representing an earnings surprise of +6.25% [1] - The company posted revenues of $826.2 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.15%, and up from $762.1 million year-over-year [2] - Over the last four quarters, Surgery Partners has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Market Outlook - Surgery Partners shares have increased approximately 4.9% since the beginning of the year, compared to the S&P 500's gain of 7.6% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.21 on revenues of $841.4 million, and $0.95 on revenues of $3.39 billion for the current fiscal year [7] Industry Context - The Medical Services industry, to which Surgery Partners belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Surgery Partners' stock performance [5][6]

Group 1 - Reservoir Media, Inc. reported a quarterly loss of $0.01 per share, consistent with the Zacks Consensus Estimate, and the same loss as the previous year [1] - The company posted revenues of $37.16 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.47%, and up from $34.32 million year-over-year [2] - Reservoir Media shares have declined approximately 13.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] Group 2 - The earnings outlook for Reservoir Media is mixed, with the current consensus EPS estimate at $0.05 on revenues of $43.22 million for the upcoming quarter, and $0.16 on revenues of $166.56 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Media Conglomerates sector is in the bottom 27% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] Group 3 - The estimate revisions trend for Reservoir Media was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Ocular Therapeutix reported a quarterly loss of $0.39 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, and compared to a loss of $0.24 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $13.46 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.7%, and down from $16.44 million in the same quarter last year [2] - Over the last four quarters, Ocular Therapeutix has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Performance - Ocular Therapeutix shares have increased by approximately 44.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $14.99 million, and for the current fiscal year, it is -$1.42 on revenues of $56.55 million [7] - The estimate revisions trend for Ocular Therapeutix was unfavorable ahead of the earnings release, which may impact future stock movements [6] Industry Context - The Medical - Drugs industry, to which Ocular Therapeutix belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of +87.3%, with revenues projected to be $1.7 million, up 32.8% from the previous year [9]

Financial Performance - EVgo Inc. reported a quarterly loss of $0.1 per share, which was better than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of +23.08% [1] - The company posted revenues of $98.03 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 13.80%, compared to revenues of $66.62 million a year ago [2] - Over the last four quarters, EVgo has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - EVgo shares have declined approximately 12.8% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current Zacks Rank for EVgo is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $91.68 million, and for the current fiscal year, it is -$0.44 on revenues of $354.7 million [7] - The outlook for the automotive industry, where EVgo operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for performance [8]

Core Insights - LGI Homes reported quarterly earnings of $1.36 per share, exceeding the Zacks Consensus Estimate of $1.21 per share, but down from $2.48 per share a year ago [1] - The earnings surprise was +12.40%, while the previous quarter saw a significant miss with actual earnings of $0.46 compared to an expected $0.75, resulting in a surprise of -38.67% [2] - The company generated revenues of $483.49 million for the quarter, surpassing the Zacks Consensus Estimate by 1.14%, but down from $602.5 million year-over-year [3] Earnings Outlook - The future performance of LGI Homes' stock will largely depend on management's commentary during the earnings call and the sustainability of the recent price movements [4] - The stock has underperformed the market, losing about 38.9% year-to-date compared to the S&P 500's gain of 7.6% [4] - Current consensus EPS estimate for the upcoming quarter is $2.06 on revenues of $630.67 million, and for the current fiscal year, it is $5.83 on revenues of $2.16 billion [8] Industry Context - The Real Estate - Development industry, to which LGI Homes belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [6] - The unfavorable trend in estimate revisions prior to the earnings release has resulted in a Zacks Rank 5 (Strong Sell) for LGI Homes, indicating expected underperformance in the near future [7]